Aldeyra Therapeutics Inc. (ALDX) reported results from its Phase 2a clinical trial of topical ocular ADX-102 in patients with dry eye disease Tuesday morning. The results showed statistically and clinically significant improvement across multiple sign and symptom endpoints.
from RTT - Before the Bell http://ift.tt/2f5Oc0F
via IFTTT
No comments:
Post a Comment